Medical/Pharmaceuticals
NORROY BIOSCIENCE Granted FDA Breakthrough Therapy and Fast Track Designations for Kidney Cancer Imaging Product
WUXI, China, Aug. 19, 2026 /PRNewswire/ -- NORROY BIOSCIENCE (NORROY), a clinical-stage biotechnology company focused on innovative targeted radiopharmaceuticals, announced that the U.S. Food and Drug Administration (FDA) has granted both Breakthrough Therapy and Fast Track designations to NORRO...
Strong growth from Vyepti® and focused commercial execution drive total revenue growth of +16% CER (+13% CER underlying) in H1 2026
VALBY, Denmark, Aug. 19, 2026 /PRNewswire/ -- Key highlights Lundbeck's total revenue grew by +16% CER[1] (+11% DKK) to DKK 13,588 million in the first six months of 2026, with the U.S. and Europe delivering double-digit growth. The performance reflected continued strong commercial momentum, dr...
Everest Medicines Announces Interim Results for First Half of 2026
SHANGHAI, Aug. 19, 2026 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the discovery, clinical development, manufacturing, and commercialization of innovative therapeutics, today announced its interim results for the first hal...
GSK's Blenrep (belantamab mafodotin) combinations approved in Singapore for treatment of relapsed/refractory multiple myeloma
* Two head-to-head phase III trials demonstrated superior efficacy, including overall survival versus a daratumumab-based triplet in DREAMM-7 * Blenrep, a first-in-class anti-BCMA ADC, could transform treatment as early as first relapse where additional effective treatment options are needed [...
Ping An Good Doctor Announces 2026 Interim Results
Corporate Health Management Business Grows Steadily; AI Healthcare Empowerment Drives Continued Profitability Improvement HONG KONG, Aug. 19, 2026 /PRNewswire/ -- Ping An Healthcare and Technology Company Limited("Ping An Good Doctor" or the "Company"; Stock Code: 1833.HK) announced its interim ...
Antengene Presents Key R&D Highlights at the Evercore 2nd China Biotech Summit
SHANGHAI and HONG KONG, Aug. 19, 2026 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leading innovative, commercial-stage global biotech company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class medicines for autoimmune dis...
CARsgen Therapeutics Announces 2026 Interim Results
SHANGHAI, Aug. 18, 2026 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on developing innovative CAR T-cell therapies, has announced its 2026 Interim Results. Business Highlights * Cash and cash equivalents were around RMB1,400 million as of June ...
Piramal Pharma Limited Completes Acquisition of Controlling Stake in Yapan Bio Private Limited
* Yapan Bio Private Limited specializes in process development, characterization, and phase I and II GMP manufacturing services for vaccines and biologics. * Piramal has held a stake in Yapan Bio since 2021, enabling the Company to provide a broad range of capabilities across biologics develo...
/C O R R E C T I O N -- Rayence/
In the news release, Rayence Breaks the Boundaries of Point-of-Care Imaging with the Launch of Integrated Portable X-ray Diagnostic Solutions 'Anywhere-M' and 'Anywhere-V', issued 18-Aug-2026 by Rayence over PR Newswire, we are advised by the company that the first paragraph has been updated and ...
GenScript Reports 27.3% First-Half 2026 Revenue Growth as AI Drug Discovery Business Doubles
Adjusted net profit surges 203.3% as Gene-to-Protein generates two-thirds of GenScript Life Science Group revenue PISCATAWAY, N.J., Aug. 18, 2026 /PRNewswire/ -- GenScript Biotech Corporation (HKEX: 1548) reported first-half revenue of approximately US$404.2 million on a comparable basis, up 27....
Frost & Sullivan: Juno Health Receives the 2026 North American Modular EHR Delivery Customer Value Leadership Recognition for Excellence in Cloud-Native EHR Innovation
The company stands out for delivering a scalable, cloud-native platform that enhances customer experience through flexible system ownership, operational efficiency, and cost-effective EHR modernization. SAN ANTONIO, Aug. 18, 2026 /PRNewswire/ -- This week we would like to congratulateJuno Health...
Harbour BioMed Announces NMPA Approval of IND Application for HBM7004 for the Treatment of Advanced Solid Tumors
CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SHANGHAI, Aug. 18, 2026 /PRNewswire/ -- Harbour BioMed (the "Company"; HKEX: 02142), a global biopharmaceutical company committed to the discovery and development of novel antibody therapeutics in immunology, oncology and other disease areas, today an...
WuXi XDC Achieves GMP Release of BCM3 Facility at Singapore Site, Enabling Global Clients with Professional Excellence
SINGAPORE, Aug. 18, 2026 /PRNewswire/ -- WuXi XDC Cayman Inc. ("WuXi XDC", stock code: 2268.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO) focused on the bioconjugate industry, today announced that its BCM3 dual-function production line for antibody i...
Enginprime Medical Closes $12M Series A Financing
Round exclusively led by Qiming Venture Partners; proceeds to fund China registration trial and overseas early-stage clinical development SHANGHAI and HANGZHOU, China, Aug. 17, 2026 /PRNewswire/ -- Enginprime Medical ("Enginprime" or the "Company"), a developer of percutaneous ventricular assist...
Connext Completes Enrollment in Phase 2 Trial of CNT201 in Dupuytren's Contracture
- All 56 planned participants enrolled approximately five months after first patient dosing - Topline Phase 2 data expected in late 2026 - Positive data could support expansion of CNT201 into Peyronie's disease and cellulite SEOUL, South Korea, Aug. 17, 2026 /PRNewswire/ -- Connext, a specialty...
U.S. Recruitment for Ohio State University Study Evaluating EmeTerm in Adults With Chronic Nausea and Vomiting
VANCOUVER, BC, Aug. 17, 2026 /PRNewswire/ -- Participant recruitment information for a clinical study being conducted at The Ohio State University has been publicly posted on ClinicalTrials.gov. The study, titled "Evaluating the Effect of Wearing a TENS Device in Nausea Relief," is also known as ...
Insilico Medicine Included in MSCI Global Small Cap Indexes, Gaining Capital Market Endorsement in Core Strengths
CAMBRIDGE, Mass., Aug. 17, 2026 /PRNewswire/ -- Insilico Medicine ("Insilico", HKEX: 3696), a clinical-stage drug discovery company powered by generative artificial intelligence (AI), announced that it will be included in MSCI Global Small Cap Indexes compiled by Morgan Stanley Capital Internatio...
OncoC4 Announces First Patient Dosing in Phase 1 Clinical Trial of ONC-783 for the Treatment of Advanced Solid Tumors
— ONC-783 is the first-and-only clinical-stage T-cell engager targeting a cancer-specific glycoform of CD24 (neoCD24) — — Subcutaneous formulation designed to provide gradual systemic exposure, potentially mitigating CRS risk — ROCKVILLE, Md., Aug. 17, 2026 /PRNewswire/ -- OncoC4 Inc., a late c...
Kelun-Biotech Announces 2026 Interim Results
CHENGDU, China, Aug. 17, 2026 /PRNewswire/ -- Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. ("Kelun-Biotech" or the "Company", Stock Code: 6990.HK) announces its unaudited consolidated results for the period ended 30 June 2026 (the "Reporting Period"). Key information is as follows: * Re...
Henlius and Sandoz Enter Strategic Collaboration to Unlock Global Value of Biosimilars Platform
* Collaboration may cover up to 10 proposed monoclonal antibody (mAb) and/or antibody-drug conjugate (ADC) biosimilar assets, with the majority of programs at early development stages * Based on the initial arrangements, the total invoiced amount expected to be achieved by Henlius in 2026 is ...
Week's Top Stories
Most Reposted
BoomerangFX Launches ChatGPT AI Search Advertising for Aesthetic, Wellness and Private-Pay Healthcare Practices, Powered by AUVIA™ AI Clinic Co-Pilot
[Picked up by 1315 media titles]
2026-11-17 23:03Manulife announces Subordinated Debenture issue
[Picked up by 1205 media titles]
2026-11-17 06:45vVardis Raises $175 Million Ahead of NYSE IPO: NYSE Content Update
[Picked up by 1188 media titles]
2026-11-13 22:11The NYSE Welcomes vVARDIS as a Publicly Listed Company
[Picked up by 1176 media titles]
2026-11-14 13:23Cision Introduces AI-Powered Cision Intelligence to Help Brands See More and Act with Confidence
[Picked up by 1172 media titles]
2026-11-12 23:00